

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

**VOLUNTARY ANNOUNCEMENT
ENTERING INTO EXCLUSIVE LICENSING AGREEMENT WITH
BOEHRINGER INGELHEIM IN RELATION
TO SIM0709 (TL1A/IL23P19 BISPECIFIC ANTIBODY)**

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on January 26, 2026, a subsidiary of the Company, Simcere Pharmaceutical Co., Ltd. (先聲藥業有限公司) (“**Jiangsu Simcere**”), entered into an exclusive licensing agreement (the “**License Agreement**”) with Boehringer Ingelheim (“**BI**”). Under terms of the License Agreement, BI would have the exclusive global rights, outside of Greater China, of SIM0709, a TL1A/IL-23p19 bispecific antibody for inflammatory bowel disease (“**IBD**”). This licensing further validates the innovation capabilities and technological leadership of the Group’s autoimmune research and development platform.

Pursuant to the License Agreement, the Group is eligible to receive an upfront payment of EUR42 million as well as success-based development, regulatory and sales milestones of up to EUR1,016 million. The Group is also eligible for tiered royalties on net sales outside Greater China.

ABOUT SIM0709

SIM0709 is a long-acting humanized bispecific antibody independently developed by the Group using proprietary multi-specific antibody platform. By simultaneously targeting tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), SIM0709 blocks two core pathways involved in the onset and progression of IBD. In both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, even outperforming the combination of the two corresponding monotherapies.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company. The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

ABOUT BI

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, January 27, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.